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In 1998, the Centers for Disease Control and Prevention was notified of
severe illnesses and one death, temporally associated with yellow fever
(YF) vaccination, in two elderly U.S. residents. Because the cases were
unusual and adverse events following YF vaccination had not been studied,
we estimated age-related reporting rates for systemic illness following YF
vaccination. We found that the rate of reported adverse events among eld-
erly vaccinees was higher than among vaccinees 25 to 44 years of age. We
also found two additional deaths among elderly YF vaccinees. These data
signal a potential problem but are not sufficient to reliably estimate inci-
dence rates or to understand potential underlying mechanisms; therefore,
enhanced surveillance is needed. YF remains an important cause of severe
illness and death, and travel to disease-endemic regions is increasing. For
elderly travelers, the risk for severe illness and death due to YF infection
should be balanced against the risk for systemic illness due to YF vaccine.
In 1998, the Centers for Disease Control and Prevention
(CDC) was notified of severe illnesses occurring days after
immunization with yellow fever (YF) vaccine in two elderly
U.S. residents. Both vaccinees had been in good health, and
neither was immunocompromised. One patient died.
Because these cases were unusual and the risk for illness fol-
lowing vaccination with YF vaccine in the elderly had not
been studied, we estimated age-related reporting rates for
YF vaccine associated systemic illness.
YF is an acute febrile illness caused by a mosquito-borne
flavivirus (1). Clinical presentation ranges from a mild,
febrile illness to a life-threatening infection involving
hepatic failure, renal dysfunction, myocardial injury, and a
bleeding diathesis. YF is endemic in much of tropical South
America and sub-Saharan Africa (2).
Two live, attenuated YF vaccines were developed in the
early 1930s, the French neurotropic vaccine (FNV) and the
17D vaccine (1,3-5). Production of FNV was halted in 1982
because its neurotropism had resulted in cases of encephali-
tis, primarily among children (1,6,7). Derivatives of the 17D
strain are the only YF virus strains currently used for vac-
cine production. These vaccines are not cloned from a single
virus but consist of a heterologous population of virions (8).
Human trials with the 17D YF vaccine in the 1930s found
low rates of adverse events and protective levels of YF viral
neutralizing antibodies in more than 95% of vaccinees (3,5).
More recent studies have shown that protective antibodies
may last 30 to 35 years (9). 
Early field trials and experiments with the 17D virus
demonstrated that virulence varied with the passage level.
Some substrains were overattenuated and led to low rates of
seroconversion, while others were associated with post-vac-
cine encephalitis (10,11). A seed lot system, which standard-
izes vaccine preparation and limits passage of the virus, was
recognized as the production standard in 1945 (1,12). The
World Health Organization publishes recommended stan-
dards. Previous reports of YF adverse events have focused
primarily on hypersensitivity or neurologic sequelae. A
review of reports submitted to the Vaccine Adverse Event
Reporting System (VAERS) in the United States from 1990
to 1997 found a rate of probable anaphylaxis after YF vac-
cine immunization of 1 per 131,000 vaccine doses distributed
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(13). Since the seed lot system was introduced, 21 cases of
post-vaccine encephalitis have been reported worldwide (20
patients recovered, one died) (1,14); 16 (76%) of these cases
occurred in children <9 months. Meningoencephalitis has on
rare occasions been reported among adults after immuniza-
tion with the vaccine (15,16), and severe, multisystemic ill-
ness has recently been reported in seven YF vaccinees (17-
19). 
YF vaccine has had a long history of efficacy and pre-
sumed safety (1). Nonetheless, a reexamination of its safety
profile has been prompted by its increased use in interna-
tional travelers and by these recent reports of serious
adverse events (17-19).
Methods
Adverse events following vaccination with YF vaccine
reported to VAERS were collected and categorized as sys-
temic, nonsystemic, or unrelated and were classified by age
group. The number of doses administered by age group
(denominators) was estimated from the age distribution of
travelers receiving the vaccine at a sample of travel clinics
and from the number of doses distributed to civilians in the
United States by the vaccine manufacturer. Reporting rates
for systemic and nonsystemic adverse events were calculated
by dividing the events reported by an estimate of the number
of people receiving the vaccine in each age group. 
Source of Cases and Case Classification
VAERS, a passive surveillance system for adverse
events, monitors vaccine safety in the United States and is
jointly operated by CDC and the U.S. Food and Drug Admin-
istration (20). All civilian U.S. VAERS reports from 1990
through 1998 listing YF vaccine were reviewed. Reports of
death, hospitalization or disability, a life-threatening illness,
or illness requiring an emergency room or doctor visit were
analyzed. Reports that did not involve any of these events
were considered less serious and were excluded from analy-
sis. Reports were blinded for age and reviewed indepen-
dently by three physicians. Adverse events were classified as
neurologic, multisystemic, uncomplicated neurologic or sys-
temic, nonspecific, hypersensitivity, local reactions, or unre-
lated (Table 1). If more than one category was appropriate,
the most serious category, in terms of reaction to the specific
vaccine components, was selected. These categories were
defined for the purposes of this study and reflect an interest
in examining adverse events that might be related to the
vaccine virus rather than those that might be immune
responses to other vaccine components. The investigators
reached a consensus on the categorization of each report
before unblinding the ages. 
A systemic adverse event (SyAE) was defined as a multi-
systemic (excluding anaphylactic) or neurologic reaction.
Adverse events categorized as uncomplicated neurologic or
systemic, hypersensitivity, or local reaction were defined as
other adverse events (OAE). A second analysis used a more
stringent definition of SyAE that included only neurologic or
multisystemic cases requiring hospitalization or resulting in
death (SyAE*).
VAERS reports that did not include the age of the vac-
cinee, provided another explanation of the adverse event
(e.g., local reaction from another vaccination), or indicated
inappropriate administration or inadvertent use (e.g., during
pregnancy) were excluded. Reports from children <15 years
of age and military personnel were excluded because no ade-
quate estimates of the number of persons who received YF
vaccine in these groups were available. As a comparison,
similar analyses were done on adverse events after hepatitis
A (HA) vaccine reported to VAERS during 1994 to 1998
(Table 1).
VAERS solicits reports not only of events known to be
causally related to vaccine but also of all events temporally
related to vaccination, some of which may be coincidental.
Evaluating the causal relationship of an event to a specific
vaccine may be also confounded by the routine practice of
administering multiple vaccines at a single visit.
Furthermore, VAERS has several other methodologic limita-
tions inherent to passive surveillance systems, such as
under-, biased-, and incomplete reporting and lack of consis-
tent diagnostic criteria. Thus, VAERS reporting rates are, at
best, a crude estimate of event rates. Given these limitations
of passive surveillance systems, neither reporting rates nor
Table 1. Categories of vaccine adverse eventsa
Neurologic (SyAE)
• Guillain-Barré syndrome, new onset seizures, encephalitis, 
myelitis, altered mental status, focal cranial or peripheral 
neurologic deficits, paresthesias, vertigo, headaches 
(headaches alone are not sufficient for neurologic diagnosis)b
• Onset <2 weeks after vaccination
• Duration >72 hours
Multisystemic (SyAE)
• Myalgias, arthralgias, rhabdomyolysis, elevated 
transaminases, respiratory distress, nausea, vomiting, 
diarrhea, nephropathy, disseminated intravascular 
coagulation, +/-feverb
• Onset <2 weeks after vaccination
• Duration >72 hours
Neurologic/systemic, uncomplicated (OAE)
• Cases that met the neurologic or systemic criteria but had a 
full and rapid clinical recovery in <72 hours
Nonspecific events without other focal finding (OAE)
• Dizziness, headache 
• Nausea, vomiting, or diarrhea alone
Hypersensitivity (OAE)
• Rash, urticaria, +/- fever
• Anaphylaxis, angioedema
• Onset within 48 hours of vaccination
Local reaction (OAE)
• Localized pain, swelling, erythema, or warmth (at injection 
site)
• Onset within 1 week of vaccination
Unrelated to vaccine (excluded from AE analysis)
• A clear, alternative diagnosis confirmed by laboratory criteria 
accounts for symptoms and signs; sometimes this is an 
underlying illness
• Another cause implied or stated in the physician's report
• For hepatitis A vaccine, onset of adverse event is >6 weeks 
SyAE = systemic adverse event; OAE = other adverse events; AE = adverse
event(s).
aListed in order from most to least severe. 
bExamples, but not limited to these signs, symptoms and conditions.Research
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the number of events reported to VAERS may automatically
be considered synonymous with the incidence of adverse
events. Elevated VAERS reporting rates may best serve as
sentinel signals suggesting hypotheses to test in other more
rigorous databases before definitive conclusions can be
reached.
Denominator
The sole manufacturer of YF vaccine in the United
States (now known as Aventis Pasteur) provided the annual
number of YF vaccine doses purchased by civilian providers
from 1995 through 1998. The annual number of doses from
1990 through 1994 was extrapolated from the number of
doses in 1995. We assumed that the number of doses
increased each year at the same annual rate as occurred
from 1995 to 1996. Doses for 1997 and 1998 were not used in
the extrapolation because unusual supply and regulatory
issues influenced the number of doses provided in these
years. Telephone interviews with health-care providers indi-
cated little or no waste of YF vaccine, which for civilian use
in the United States is sold predominantly in single-dose
vials. Thus, it was assumed that the total number of doses
sold was a good estimate of the total number of doses admin-
istered.
The manufacturers of HA vaccine (Havrix, SmithKline
Beecham, Rixensart, Belgium; and Vaqta, Merck & Co., Inc.,
West Point, PA) provided the annual number of doses of HA
vaccine purchased from 1995 through 1998. We estimated
that 10% of HA vaccine was wasted and that 50% of vac-
cinees received both doses in the series. The total number of
doses sold was reduced by these amounts to estimate the
total number of doses administered. These doses did not
include those used for outbreak control.
Thirteen U.S.-based GeoSentinel clinics, which provide
YF vaccine to international travelers, reviewed records of YF
and HA vaccine administration. GeoSentinel is an interna-
tional network of travel and tropical medical clinics estab-
lished in 1995 as a
collaborative effort by
CDC and the Interna-
tional Society of Travel
Medicine (21). GeoSenti-
nel monitors geographic
and temporal infectious
disease trends among
people crossing interna-
tional borders; the clin-
ics are chosen to detect
sentinel events in travel-
ers seen in clinics before
and after travel. Within
the United States, these
clinics are considered
representative of clinics
that offer YF vaccine. All
YF and HA vaccine
recipients during the
most recent 12-month
period for which com-
plete information was
available were catego-
rized by age group (15 to
24 years, 25 to 44 years, 45 to 64 years, 65 to 74 years, and
>75 years). Data for children <15 years of age and military
personnel were excluded because these groups are underrep-
resented at U.S. GeoSentinel clinics. Other than these excep-
tions, the age distribution for YF vaccine recipients at
GeoSentinel clinics was assumed to represent national YF
vaccine use. The age distribution for HA vaccine recipients
from these clinics was also assumed to represent national
use excluding the same exceptions and outbreak control.
The number of YF vaccine doses administered to each
age group was estimated by multiplying the total number of
YF vaccine doses per year by the proportionate age group
distribution estimated from the GeoSentinel clinics. Age
group-specific reporting rates for SyAE per 100,000 doses
and reporting rate ratios for SyAE were calculated with a
reference group of 25- to 44-year-old vaccine recipients. The
25- to 44-year-old group was chosen because of the previ-
ously reported increased risk for adverse events among
younger YF vaccine recipients (1). Although the risk is high-
est for infants <4 months of age, it is unclear at what age the
risk reaches a nadir. Confidence intervals were calculated
based on standard statistical assumptions for confidence
intervals (CI) for ratios of rates, although because of the lim-
itations of passive surveillance systems, these assumptions
may not hold.
Results
From 1990 through 1998, VAERS received 166 reports
of YF vaccine adverse events that met the criteria for review
(Figure 1). Thirty-five (21%) of these reports were catego-
rized as SyAEs and 36 (22%) as OAEs. Of the 10 VAERS
reports for patients >65 years of age, one was categorized as
an OAE and the other nine as SyAE. The latter included the
two index patients, one additional death, and six patients
with various signs and symptoms, including fever, headache,
malaise, myalgia, nausea, somnolence, and ataxia. Two of
these six patients were hospitalized. Ninety-five (57%)
Figure 1. Diagram of yellow fever (YF) vaccine adverse events reports (1990-1998). n = number of reports; O =
number of reports in patients >65 years old. VAERS = Vaccine Adverse Event Reporting System.Research
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reports were excluded because they did not include the age of
the vaccinee (4 reports), or the vaccine was used in military
personnel (56 reports) or a child <15 years old (7 reports), or
an alternative cause of the adverse event was reported (28
reports). Seventeen patients were hospitalized, and three
patients, ages 63, 67, and 79 years, died. The clinical course
for the two index patients and the two additional deaths was
characterized by a nonspecific febrile syndrome with fatigue,
myalgia, and gastrointestinal symptoms, rapidly progressing
to a severe multisystemic illness with dysfunction of liver,
kidneys, lungs, central nervous system, as well as throm-
bocytopenia, and possible disseminated intravascular coagu-
lopathy (18).
From 1990 through 1998, U.S. civilian providers pur-
chased an estimated 1.55 million doses of YF vaccine. The
age distribution of YF vaccine recipients was estimated from
5,125 YF vaccine recipients in 13 GeoSentinel clinics. The
reference group, ages 25 to 44 years, accounted for 45% of
the sample; 285 (5.6%) of the vaccinees were 65 to 74 years of
age, and 73 (1.4%) were >75 years of age (Figure 2). 
The overall reporting rate for a SyAE after YF vaccina-
tion was 2.4 per 100,000 doses, and the reporting rate for
death was 0.2 per 100,000 doses; for those >65 years of age,
the overall reporting rate for SyAE was 8.3 per 100,000
doses, and the reporting rate for death was 1.8 per 100,000
doses. During this period, an estimated 108,000 doses were
administered to those >65 years of age. The reporting rate
for a SyAE for the reference age group (25 to 44 years) was
1.6 per 100,000 doses and increased progressively for each
older age group to 5.8 per 100,000 doses for vaccinees 65 to
74 years of age and 18.1 per 100,000 doses for those  >75
years of age (Table 2). Compared with the reference group,
the reporting rate ratio for an SyAE for those 65 to 74 years
of age was 3.7 (95% CI 1.3-10.7); for those >75 years of age, it
was 11.6 (95% CI 3.7-36.3). Conversely, the reporting rate
for OAE decreased for each older age group. 
When analysis of SyAEs was restricted to vaccinees who
died or were hospitalized, the pattern was even stronger
(Table 3). Compared with the reference group, the reporting
rate ratio for an SyAE* for those 65 to 74 years of age was
12.3 (95% CI 2.0-73.2); for those >75 years of age, it was 31.8
(95% CI 4.5-225.9).
Of the 35 patients with SyAEs, 19 (54%) received at
least one other vaccine in addition to YF vaccine. When
analysis was restricted to those who received only YF vac-
cine, the reporting rate ratio for a SyAE* for those 65 to 74
years of age was 6.1 (95% CI 1.4-27.3); for those >75 years of
age it was 23.9 (95% CI 5.3-106.6). Six of the nine patients
>65 years of age with SyAEs received only YF vaccine, and
all five patients  >65 years of age who were hospitalized or
died had received that vaccine alone. 
During 1995 to 1998, VAERS received 310 reports of
adverse events after immunization with HA vaccine that
met the inclusion criteria. From an estimated 3.2 million
doses of HA vaccine, 30 patients were hospitalized, and none
died. This is double the total number of doses of YF vaccine
and almost three times the number of YF vaccine doses
given to people ages  >75 years. The reporting rate for an
SyAE after HA vaccine for vaccine recipients 65 to 74 years
of age was 6.2 per 100,000. This was higher than the 2.5 per
100,000 reporting rate for the reference group (ages 25 to 44
years); however, there was no consistent increase in the
reporting rate for SyAE for each older age group, and recipi-
ents ages >75 years did not have a different reporting rate
from those ages 25 to 44 years (reporting rate ratio =1.9, 95%
CI 0.6-6.3) (Table 4) (Figure 3). 
Discussion
Severe illness in two elderly recipients of YF vaccine,
one of whom died shortly after immunization, prompted this
collaborative study, which examined reporting rates for
adverse events among elderly YF vaccine recipients in the
United States (18). We found a higher reporting rate for
SyAEs among elderly YF vaccine recipients than among YF
vaccine recipients ages 25 to 44 years. This increase in
reporting rates persisted when adverse events were limited
Table 2. Reporting rates (RR) and reporting rate ratios (RRR) for yellow fever (YF) vaccine adverse events by age, 1990–1998
Age 
(years)
No.
vaccine 
doses No. OAEa OAE reports/
100,000 doses RRR (95% CI) No. SyAEb SyAE reports/ 
100,000 doses RRR (95% CI)
15-24 189,991 11 5.79 2.5 (1.2-5.5) 3 1.58 1.0 (0.3-3.6)
25-44 702,783 16 2.28 Reference 11 1.57 Reference
45-64 442,605 8 1.81 0.8 (0.3-1.9) 12 2.71 1.7 (0.8-3.9)
65-74 86,222 1 1.16 0.5 (0.1-3.8) 5 5.80 3.7 (1.3-10.7)
>75 22,085 0 0 undefined 4 18.11 11.6 (3.7-36)
Total 1,443,686 36 2.49 35 2.42
CI = confidence interval.
aOAE: other adverse event (uncomplicated neurologic/systemic, hypersensitivity, or local reaction).
bSyAE: systemic adverse event (multisystemic [excluding anaphylactic] or neurologic reaction)
Figure 2. Estimated age range for YF vaccine recipients, n=5,125.
Percentage of children <15 years of age is underestimated as these
groups were excluded from analysis (see text). Research
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sis of these isolates and the elevated antibody titers suggest
an overwhelming infection caused by the selective amplifica-
tion of a mutated virus subpopulation. The temporal rela-
tionship between severe illness and YF vaccination, the
similar clinical presentations, and the laboratory results
favor the hypothesis that these adverse events are causally
related to YF vaccine. Recently, three cases of similar sys-
temic adverse events after YF vaccination resulting in death
were reported: two from Brazil, patients ages 5 and 22 years
(Brazilian 17DD vaccine) and one from Australia, patient 56
years old (17D-204 vaccine) (17,19).
An increased risk for severe disease due to the vaccine
strain of Yellow fever virus among older YF vaccine recipi-
ents is biologically plausible. Numerous reports and studies
have shown that deaths and severe illnesses occur more fre-
quently among the elderly with other flaviviral infections
(e.g., West Nile encephalitis, Japanese encephalitis, Saint
Louis encephalitis, Murray Valley encephalitis, and tick-
borne encephalitis), while these infections are more likely to
be self-limited in children (24-27). Similarly, investigations
of YF outbreaks in the 1930s and 1940s found increased
case-fatality rates among the oldest patients (28-30). 
This study has several limitations. Rates calculated
from VAERS data have to be interpreted with caution
because of the problems inherent in a passive reporting sys-
tem. Estimates of adverse events based on VAERS reports
are likely to underestimate actual events (31). Our data,
Table 3. Reporting rates (RR) and reporting rate ratios (RRR) for serious systemic yellow fever (YF) vaccine adverse events (SyAE*) by age,
1990–1998
 Age 
(years)
No. 
vaccine 
doses
No. of
OAE*a
OAE* reports/
100,000 doses RRR (95% CI) No. SyAE*b
SyAE* reports/  
100,000 doses RRR (95% CI)
15-24 189,991 12 6.32 1.8 (0.9-3.5) 2 1.05 3.7 (0.5-26)
25-44 702,783 25 3.56 Reference 2 0.29 Reference
45-64 442,605 15 3.39 1.0 (0.5-1.8)  5 1.13 4.0 (0.8-20)
65-74  86,222 3 3.48 1.0 (0.3-3.2) 3 3.48 12.3 (2.0-73)
  >75  22,085 2 9.06 2.5 (0.6-10.7) 2 9.06  32 (4.5-226)
Total 1,443,686 57 3.95 14 0.97
CI = confidence intervals.
aOAE*= other adverse events (i.e., uncomplicated neurologic or systemic event; hypersensitivity; local reaction) OR systemic adverse events not requiring
hospitalization or resulting in death. 
bSyAE* = serious systemic adverse events, including only neurologic or multisystemic adverse events requiring hospitalization or resulting in death; this is
distinguished from the term SyAE, which indicates all systemic adverse events (See Table 2).
Table 4. Reporting rates (RR) and reporting rate ratios (RRR) for hepatitis A vaccine adverse events by age, 1995–1998
Age 
(years)
No. HA 
doses
No. 
OAEa
OAE reports/ 
100,000 doses RRR (95% CI) No. SyAEb
SyAE reports/ 
100,000 doses RRR (95% CI)
15-24 387,031 21 5.43 1.8(1.1-3.0) 7 1.81 0.7 (0.3-1.6)
25-44 1,444,895 44 3.05 Reference 36 2.49 Reference
45-64 1,096,391 23 2.10 0.7 (0.4-1.1) 26 2.37 1.0 (0.6-1.6)
65-74 241,453 4 1.66 0.5 (0.2-1.5) 15 6.21 2.5(1.4-4.6)
>75 61,760 1 1.62 0.5 (0.1-3.9) 3 4.86 1.9 (0.6-6.3)
Total 3,231,530 93 2.88 87 2.69
HA = hepatitis A [vaccine]; CI = confidence intervals.
aOAE = other adverse events (uncomplicated neurologic/systemic, hypersensitivity, or local reaction).
bSyAE: systemic adverse event (multisystemic [excluding anaphylactic] or neurologic reaction)
to patients who required hospitalization or died and when
recipients who also received other vaccines were excluded.
Although we did find an elevated rate of reported SyAEs fol-
lowing HA vaccine in the 65- to 74-year-old group, we did not
find a similar increase in persons >75 years, despite almost
three times as many doses sold overall and twice as many
adverse events reported to VAERS for all age groups com-
bined. No deaths following HA vaccination were reported.
Our analysis showed that the reporting rate for systemic
illness requiring hospitalization or leading to death after YF
vaccination was 3.5 per 100,000 among people 65 to 75 years
of age and 9.1 per 100,000 for people >75 years. For a rough
comparison, the risk for vaccine-associated paralytic polio-
myelitis due to oral polio vaccine was estimated as 1 per 2.5
million (22,23). A review of a passive surveillance system in
the United Kingdom that receives reports from primary-care
physicians also found a similar increase in SyAEs among eld-
erly YF vaccine recipients (unpub. data).
Close examination of the two index cases and two addi-
tional deaths that followed YF vaccination shows four cases
with similar clinical presentations, all of which share impor-
tant characteristics with viscerotropic wild-type YF infection
(18). Clinical presentations were characterized by fever,
myalgia, headache, and confusion rapidly progressing to a
multisystemic illness and death in three of the patients. The
vaccine strain of YF virus was isolated from the serum of two
patients and the cerebrospinal fluid of one. Sequence analy-Research
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therefore, may reflect minimum estimates of these adverse
events. Age-related reporting bias may also have influenced
our results. Age-related reporting bias would decrease the
significance of the reporting rate ratios only if SyAEs, partic-
ularly those leading to hospitalization and death, among
vaccinees <65 years of age were reported less often than
among vaccinees >65 years of age. 
Another important limitation is that the estimated age
distribution of travelers from the GeoSentinel clinics receiv-
ing YF vaccine in 1998 was assumed to apply for the entire
study (1990 to 1998) and to be generalizable to the entire
United States. However, if as many suspect, the proportion
of elderly travelers has increased in recent years, this
extrapolation will have overestimated the number of older
travelers and have the effect of underestimating the report-
ing rate and reporting rate ratio of adverse events in the eld-
erly. We excluded data on children <15 years of age, which
caused a slight, proportionate increase in the denominator
for the remaining vaccine recipients and a slight underesti-
mate of the reporting rate for adverse events in all other age
groups. Also, the calculation of denominators relied on
assuming that the increase in vaccines administered
between 1995 and 1996 held for 1990 to 1994. 
An additional limitation is that age-specific SyAEs to YF
vaccine may reflect an age-related response to vaccines in
general or an increased amount of background illness in the
elderly. Analysis of VAERS reports for SyAEs to HA vaccine
did not support this conclusion; however, HA vaccine is an
inactivated vaccine, and another live, attenuated vaccine
would have served as a better control. We attempted to look
at adverse events reported for oral typhoid vaccine, but the
limited number of VAERS reports precluded a quantitative
analysis.
Finally, although severe illness occurred days after YF
vaccination in the cases we investigated, this temporal asso-
ciation does not prove causality. Definitive clinical or patho-
logic evidence identifying YF vaccine as the cause of severe
illness or death for most cases reported to VAERS is lacking
and is not routinely part of this surveillance system.
YF remains an important cause of severe illness and
death in tropical South America and sub-Saharan Africa. In
recent years, Aedes aegypti, the mosquito vector of urban YF,
has reestablished itself in South America, increasing the
likelihood of large, explosive outbreaks, and in both South
America and sub-Saharan Africa, the number and size of
outbreaks have increased in the last 20 years (32-34). Con-
comitant with these changes in the distribution of the vector
and ongoing outbreaks, travel from the United States to dis-
ease-endemic regions has increased substantially (35).
Quantitative risk assessments of YF among travelers to dis-
ease-endemic areas have not been done; however, the risk for
acquiring YF has been highlighted by the recent deaths of
four unvaccinated travelers due to YF imported to Europe
and the United States (36-40).
The 17D YF vaccine has a long history of reported safety
and efficacy and has played an important role in YF control,
one of the public health triumphs of the 20th century. Age-
specific recommendations and production standards for this
important vaccine have been modified as a result of safety
and efficacy issues that have become apparent with
increased use (1,2,4,41,42). These modifications have pre-
served the vaccine as a vital tool for disease prevention and
control. Defining the risk for adverse events among elderly
vaccine recipients is an extension of these important efforts. 
Conclusion
This study provides data quantifying the relative report-
ing ratios of SyAE following YF vaccination among people
>65 years of age in the United States. However, several
issues must be addressed before any changes or restrictions
to YF vaccine recommendations are proposed. 
These SyAEs are still relatively rare (2.4 per 100,000
doses) in the United States, where an estimated 200,000
doses are given annually. The risk for unvaccinated travel-
ers acquiring YF remains undefined; so risk-benefit esti-
mates of YF vaccine are difficult to develop. In the absence of
this important information, we suggest the following steps.
Our observations should be confirmed by studies in different
populations. Enhanced surveillance for systemic adverse
events following YF vaccination should be introduced at U.S.
certified vaccination centers and in other countries where YF
vaccine is used. This enhanced surveillance should be com-
bined with prospective follow-up that includes appropriate
clinical, epidemiologic, and laboratory assessments of cases,
biologic specimens, and vaccine or vaccine lots. In addition,
epidemiologic studies should be designed to explore both
host- and vaccine-specific factors associated with systemic
adverse events (43).
In the interim, elderly YF vaccine recipients and their
health-care providers should be cautioned about the possible
risks of vaccination. Travel itineraries should be scrutinized,
and the vaccine given only to those traveling to areas that
report YF or are in the YF-endemic zone. 
YF causes serious, life-threatening infections, and the vac-
cine is highly effective. The virus is responsible for substantial
morbidity and death in disease-endemic areas and until more
definitive evidence of vaccine-related adverse events is accumu-
lated, the benefit-risk ratio of mass vaccination in YF-endemic
countries favors continuation of a universal vaccine policy
under the Expanded Programme on Immunization. Mean-
while, efforts to enhance our understanding of both the risks
and benefits of YF vaccine and refine its use to maximize its
safety and effectiveness should be accelerated.
Figure 3. Reporting rate ratios for systemic adverse events (SyAE)
and serious adverse events (SyAE*) after yellow fever (YF) vaccina-
tion and hepatitis A (HA) vaccination.Research
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